News blog
Scancell Holdings
- BY: Andrew Hore |
- POSTED: 01/02/2011 |
Cancer vaccines developer Scancell Holdings used up £1.1m of cash in the six months to October 2010.
There is still £1.74m of cash in the bank.
So far, four patients have been recruited for the melanoma clinical trials for the SCIB1 treatment. The scope of the trials is being widened to patients with stage III and stage IV malignant melanoma. The SCIB1 trials are on track but there have been delays in patient recruitment. The clinical study should still be completed by the end of 2012.
At 74p a share, Scancell is valued at £11.8m.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|